Healthcare -
Biotechnology - NASDAQ - CA
$ 2.63
1.33 %
$ 3.17 M
Market Cap
-0.23
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
InMed Pharmaceuticals Inc.
| Current Assets | 8.69 M |
| Cash & Short-Term Investments | 6.61 M |
| Receivables | 353 K |
| Other Current Assets | 1.72 M |
| Non-Current Assets | 3.13 M |
| Long-Term Investments | 0 |
| PP&E | 1.25 M |
| Other Non-Current Assets | 1.88 M |
| Current Liabilities | 1.97 M |
| Accounts Payable | 626 K |
| Short-Term Debt | 318 K |
| Other Current Liabilities | 1.03 M |
| Non-Current Liabilities | 645 K |
| Long-Term Debt | 645 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
InMed Pharmaceuticals Inc.
| Revenue | 6.29 M |
| Cost Of Revenue | 4.78 M |
| Gross Profit | 1.51 M |
| Operating Expenses | 12.6 M |
| Operating Income | -11.1 M |
| Other Expenses | -3.45 M |
| Net Income | -7.68 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
InMed Pharmaceuticals Inc.
| Net Income | -7.68 M |
| Depreciation & Amortization | 605 K |
| Capital Expenditures | -9.29 K |
| Stock-Based Compensation | 138 K |
| Change in Working Capital | -369 K |
| Others | -119 K |
| Free Cash Flow | -7 M |
Wall Street Analysts Price Targets
InMed Pharmaceuticals Inc.
INM has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
INM does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
InMed Pharmaceuticals Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
42.3 USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof) and associated short-term preferred investment option. The short-term preferred investment option issued in the offering is exercisable immediately upon issuance at an exercise price of $2.436 per share and will expire eighteen months from the effective date of the Resale Registration Statement (as defined below).
newsfilecorp.com
- 1 month ago
InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof) and associated short-term preferred investment option in a private placement priced at-the-market under Nasdaq rules. The short-term preferred investment option to be issued in the offering will be exercisable immediately upon issuance at an exercise price of $2.436 per share and will expire eighteen months from the effective date of the Resale Registration Statement (as defined below).
newsfilecorp.com
- 1 month ago
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study
Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/Gro Significantly reduces levels of inflammasome marker, NLRP3, a key contributor to neurodegeneration Reduces key pro-inflammatory markers, independent of amyloid beta or tau pathology Vancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation, further supporting its potential as a therapeutic candidate in Alzheimer's disease. The study evaluated INM-901 in an ex vivo model of lipopolysaccharide (LPS)-induced inflammation in animal brain tissue, which is designed to induce a strong expression of pro-inflammatory cytokines IL-6, IL-1β, IL-2, and KC/Gro and inflammasome marker NLRP3.
newsfilecorp.com
- 1 month ago
InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA
Vancouver, British Columbia--(Newsfile Corp. - June 13, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that Marcum LLP has resigned as InMed's auditor following the acquisition of Marcum's attest business by CBIZ CPAs P.C., with an effective resignation date of June 12, 2025 (the "Marcum Acquisition").
newsfilecorp.com
- 1 month ago
InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2025 which ended March 31, 2025. The Company's full financial statements and related MD&A for the third quarter ended March 31, 2025, are available at www.inmedpharma.com, www.sedarplus.com and at www.sec.gov.
newsfilecorp.com
- 2 months ago
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - February 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the second quarter of the fiscal year 2025 which ended December 31, 2024. The Company's full financial statements and related MD&A for the first quarter ended December 31, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
newsfilecorp.com
- 5 months ago
InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration
INM-089 IVT formulation selected for continued development Demonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a significant safety margin Dose ranging studies completed Vancouver, British Columbia--(Newsfile Corp. - February 3, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the selection of an intravitreal ('IVT') formulation for INM-089 as a drug candidate to be utilized in the Company's ongoing development program targeting the treatment of dry age-related macular degeneration ('AMD'). Michael Woudenberg, InMed's Chief Operating Officer and Senior Vice President of Chemistry, Manufacturing, and Controls, commented, "We are encouraged by the recent data demonstrating that INM-089 can be successfully delivered as an IVT formulation, offering several advantages for the continued development of this compound in the treatment of dry AMD.
newsfilecorp.com
- 5 months ago
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds
Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds Patent covers novel analog compounds for therapeutic applications in pain, glaucoma, inflammatory disease, anxiety, and a variety of neurological conditions including Parkinson's disease, Alzheimer's disease and dementia Patent also protects the methods of preparation of the compounds Vancouver, British Columbia--(Newsfile Corp. - January 22, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces it has been granted an international Patent Cooperation Treaty ('PCT') patent in the first of several jurisdictions where the patent has been filed. Titled "Cannabinoid analogs and methods for their preparation ", this patent protects the use of several proprietary small molecule compounds and methods of their preparation, including the drug candidates screened for InMed's Alzheimer's disease and dry age-related macular degeneration programs.
newsfilecorp.com
- 6 months ago
InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study
INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer's Statistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL') mRNA profile showed a reduction of several key neuroinflammatory genes in the brain Vancouver, British Columbia--(Newsfile Corp. - January 21, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces positive results from a long-term in vivo preclinical Alzheimer's Disease ('AD') study. In the study, INM-901 demonstrated a reduction in several plasma and brain markers of neuroinflammation, a recognized contributor to Alzheimer's disease development and progression.
newsfilecorp.com
- 6 months ago
InMed Announces Results of 2024 Annual General Meeting
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general meeting of shareholders held on December 18, 2024 (the "Meeting"), the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated October 28, 2024, were voted upon by the shareholders. A total of 5,318,677 common shares of the Company, representing approximately 39.83% of the Company's 13,353,431 issued and outstanding common shares, were represented in person or by proxy at the Meeting.
newsfilecorp.com
- 7 months ago
InMed Enters Into Standby Equity Purchase Agreement
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces it entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, LTD (the "Investor"), an investment fund managed by Yorkville Advisors Global LP, a global investment manager, on December 13, 2024 (the "Effective Date") to sell up to $10 million in the aggregate of the Company's common shares, no value (the "Common Shares"), at any time during the 36-month period following the Effective Date of the SEPA, subject to the effectiveness of a registration statement with the Securities and Exchange Commission and other conditions set forth in the SEPA. "This equity facility is a key component of our financing strategy, offering both flexibility and extended runway to accelerate our pharmaceutical programs and other business development initiatives," said Eric A.
newsfilecorp.com
- 7 months ago
InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System
Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effects Supports therapeutic potential of cannabinol for inflammatory skin diseases such as psoriasis, atopic dermatitis and pruritus Anti-inflammatory effects of cannabinol show potential for therapeutic and cosmetic application Vancouver, British Columbia--(Newsfile Corp. - November 19, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announced that a peer-reviewed scientific study entitled "Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes" has been published in the international journal Biofactors. This Company-sponsored study demonstrates the biological activity of cannabinol ("CBN") and its potential anti-inflammatory effects in skin diseases.
newsfilecorp.com
- 8 months ago
8. Profile
Summary
InMed Pharmaceuticals Inc. INM
COUNTRY
CA
INDUSTRY
Biotechnology
MARKET CAP
$ 3.17 M
Dividend Yield
0.00%
Description
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Contact
815 West Hastings Street, Vancouver, BC, V6C 1B4
https://www.inmedpharma.com
IPO
Date
May 5, 2014
Employees
13
Officers
Dr. Ado Muhammad
Senior Consultant of Medical Affairs
Dr. Sazzad Hossain M.Sc., Ph.D.
Co-Founder
Colin Clancy
Senior Director of Investor Relations
Ms. N. Netta Jagpal
Chief Financial Officer & Corporate Secretary
Mr. Eric A. Adams B.S. Chem., M.I.B.
President, Chief Executive Officer & Director
Ms. Alexandra Diane-Janet Mancini M.Sc.
Senior Vice President of Clinical & Regulatory Affairs
Mr. Jerry P. Griffin
Vice President of Sales & Marketing
Dr. Shane A. Johnson Ph.D.
Senior Vice President & GM of BayMedica
Mr. Michael Woudenberg P.Eng.
Chief Operating Officer
Dr. Eric Chih-Hsien Hsu Ph.D.
Senior Vice President of Preclinical Research & Development